Zobrazit více v PubMed
Dubrow R., Darefsky A.S. Demographic variation in incidence of adult glioma by subtype, United States, 1992–2007. BMC Cancer. 2011;11:325. doi: 10.1186/1471-2407-11-325.
PubMed
DOI
PMC
Krex D., Klink B., Hartmann C., von Deimling A., Pietsch T., Simon M., Sabel M., Steinbach J.P., Heese O., Reifenberger G., et al. Long-term survival with glioblastoma multiforme. Pt 10Brain. 2007;130:2596–2606. doi: 10.1093/brain/awm204.
PubMed
DOI
Zacher A., Kaulich K., Stepanow S., Wolter M., Köhrer K., Felsberg J., Malzkorn B., Reifenberger G. Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel. Brain Pathol. 2017;27:146–159. doi: 10.1111/bpa.12367.
PubMed
DOI
PMC
WHO Classification of Tumours Editorial Board, editor. WHO Classification of Tumours. 5th ed. International Agency for Research on Cancer; Lyon, France: 2021. Central nervous system tumours.568p.
Panigrahi A.R., Pinder S.E., Chan S.Y., Paish E.C., Robertson J.F., Ellis I.O. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J. Pathol. 2004;204:93–100. doi: 10.1002/path.1611.
PubMed
DOI
Wang H., Guo M., Wei H., Chen Y. Targeting p53 pathways: Mechanisms, structures, and advances in therapy. Nat. Singal Tranduct. Target. Ther. 2023;8:92. doi: 10.1038/s41392-023-01347-1.
PubMed
DOI
PMC
Wee P., Wang Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers. 2017;9:52. doi: 10.3390/cancers9050052.
PubMed
DOI
PMC
Peng Y., Wang Y., Zhou C., Mei W., Zeng C. PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway? Front. Oncol. 2022;12:819128. doi: 10.3389/fonc.2022.819128.
PubMed
DOI
PMC
Takahashi Y., Akahane T., Sawada T., Ikeda H., Tempaku A., Yamauchi S., Nishihara H., Tanaka S., Nitta K., Ide W., et al. Adult classical glioblastoma with a BRAF V600E mutation. World J. Surg. Oncol. 2015;13:100. doi: 10.1186/s12957-015-0521-x.
PubMed
DOI
PMC
Stayton C.L., Dabovic B., Gulisano M., Gecz J., Broccoll V., Glovanazzl S., Bossolasco M., Monaco L., Rastan S., BoncInelli E., et al. Cloning and characterization of a new human Xq13 gene, encoding a putative helicase. Hum. Mol. Genet. 1994;3:1957–1964. doi: 10.1093/hmg/3.11.1957.
PubMed
DOI
Gibbons R.J., Wada T., Fisher C.A., Malik N., Mitson M.J., Steensma D.P., Fryer A., Goudie D.R., Krantz I.D., Traeger-Synodinos J. Mutations in the chromatin-associated protein ATRX. Hum. Mutat. 2008;29:796–802. doi: 10.1002/humu.20734.
PubMed
DOI
Wong L.H., McGhie J.D., Sim M., Anderson M.A., Ahn S., Hannan R.D., George A.J., Morgan K.A., Mann J.R., Choo K.A. ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells. Genome Res. 2010;20:351–360. doi: 10.1101/gr.101477.109.
PubMed
DOI
PMC
Heaphy C.M., de Wilde R.F., Jiao Y., Klein A.P., Edil B.H., Shi C., Bettegowda C., Rodriguez F.J., Eberhart C.G., Hebbar S., et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science. 2011;333:425. doi: 10.1126/science.1207313.
PubMed
DOI
PMC
Pekmezci M., Rice T., Molinaro A.M., Walsh K.M., Decker P.A., Hansen H., Sicotte H., Kollmeyer T.M., McCoy L.S., Sarkar G., et al. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: Additional prognostic roles of ATRX and TERT. Acta Neuropathol. 2017;133:1001–1016. doi: 10.1007/s00401-017-1690-1.
PubMed
DOI
PMC
Han B., Cai J., Gao W., Meng X., Gao F., Wu P., Duan C., Wang R., Dinislam M., Lin L., et al. Loss of ATRX suppresses ATM dependent DNA damage repair by modulating H3K9me3 to enhance temozolomide sensitivity in glioma. Cancer Lett. 2018;419:280–290. doi: 10.1016/j.canlet.2018.01.056.
PubMed
DOI
Ohba S., Kuwahara K., Yamada S., Abe M., Hirose Y. Correlation between IDH, ATRX, and TERT promoter mutations in glioma. Brain Tumor Pathol. 2020;37:33–40. doi: 10.1007/s10014-020-00360-4.
PubMed
DOI
Alhendi A.S.N. Ph.D. Thesis. University of Leicester; Leicester, UK: 2019. [(accessed on 16 April 2019)]. Exploring the Regulation and Activation of ALT, the Alternative Lengthening of Telomeres. Available online: https://hdl.handle.net/2381/43806.
Liu J., Zhang X., Yan X., Sun M., Fan Y., Huang Y. Significance of TERT and ATRX mutations in glioma. Oncol. Lett. 2019;17:95–102. doi: 10.3892/ol.2018.9634.
PubMed
DOI
PMC
Yuzawa S., Kamikokura Y., Tanino M., Takei H. Malignant transformation of NF1-associated spinal astrocytoma with loss of ATRX expression during the course: A case report. Clin. Neuropathol. 2021;40:201–208. doi: 10.5414/NP301314.
PubMed
DOI
Bobeff E.J., Szczesna D., Bieńkowski M., Janczar K., Chmielewska-Kassassir M., Wiśniewski K., Papierz W., Wozniak L.A., Jaskólski D.J. Plasma amino acids indicate glioblastoma with ATRX loss. Amino Acids. 2021;53:119–132. doi: 10.1007/s00726-020-02931-3.
PubMed
DOI
Gülten G., Yalçın N., Baltalarlı B., Doğu G., Acar F., Doğruel Y. The importance of IDH1, ATRX and WT-1 mutations in glioblastoma. Pol. J. Pathol. 2020;71:127–137. doi: 10.5114/pjp.2020.97020.
PubMed
DOI
Chaurasia A., Park S.H., Seo J.W., Park C.K. Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival. J. Korean Med. Sci. 2016;31:1208–1214. doi: 10.3346/jkms.2016.31.8.1208.
PubMed
DOI
PMC
Ikemura M., Shibahara J., Mukasa A., Takayanagi S., Aihara K., Saito N., Aburatani H., Fukayama M. Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas. Histopathology. 2016;69:260–267. doi: 10.1111/his.12927.
PubMed
DOI
Uppar A.M., Sugur H., Prabhuraj A.R., Rao M.B., Devi B.I., Sampath S., Arivazhagan A., Santosh V. H3K27M, IDH1, and ATRX expression in pediatric GBM and their clinical and prognostic significance. Childs Nerv. Syst. 2019;35:1537–1545. doi: 10.1007/s00381-019-04222-z.
PubMed
DOI
Cai H.-Q., Wang P.-F., Zhang H.-P., Cheng Z.-J., Li S.-W., He J., Zhang Y., Hao J.-J., Wang M.-R., Yan C.-X., et al. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1R132H mutation and may predict better prognosis among glioblastomas without the IDH1 mutation and ATRX loss. J. Clin. Pathol. 2018;71:702–707. doi: 10.1136/jclinpath-2018-205000.
PubMed
DOI
PMC
Sithanandam G., Druck T., Cannizzaro L.A., Leuzzi G., Huebner K., Rapp U.R. B-raf and a B-raf pseudogene are located on 7q in man. Oncogene. 1992;7:795–799.
PubMed
Haparátová E. Maligní melanom s BRAF mutací a možnosti jeho léčby. Klin. Farmakol. 2015;29:65–68.
Kleinschmidt-DeMasters B.K., Aisner D.L., Foreman N.K. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation. Am. J. Surg. Pathol. 2015;39:528–540. doi: 10.1097/PAS.0000000000000363.
PubMed
DOI
PMC
Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954. doi: 10.1038/nature00766.
PubMed
DOI
Zheng L.M., Gong J., Zou Y., Zhang M., Yu T., Hou J., Zhou Q., Chen N. Epithelioid glioblastoma with BRAF V600E mutation: A clinicopathological and molecular study. Chin. J. Pathol. 2021;50:229–235.
PubMed
Vuong H.G., Altibi A.M.A., Duong U.N.P., Ngo H.T.T., Pham T.Q., Fung K.-M., Hassell L. BRAF Mutation is Associated with an Improved Survival in Glioma-a Systematic Review and Meta-analysis. Mol. Neurobiol. 2018;55:3718–3724. doi: 10.1007/s12035-017-0599-y.
PubMed
DOI
Chi A.S., Batchelor T.T., Yang D., Dias-Santagata D., Borger D.R., Ellisen L.W., Iafrate A.J., Louis D.N. BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults. J. Clin. Oncol. 2013;31:e233–e236. doi: 10.1200/JCO.2012.46.0220.
PubMed
DOI
Da R., Wang M., Jiang H., Wang T., Wang W. BRAFAMP Frequently Co-occurs with IDH1/2, TP53, and ATRX Mutations in Adult Patients with Gliomas and Is Associated with Poorer Survival Than That of Patients Harboring BRAFV600E. Front. Oncol. 2021;10:531968. doi: 10.3389/fonc.2020.531968.
PubMed
DOI
PMC
Wang J., Liu Z., Cui Y., Liu Y., Fang J., Xu L., He Y., Du J., Su Y., Zou W., et al. Evaluation of EZH2 expression, BRAF V600E mutation, and CDKN2A/B deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma. J. Neurooncol. 2019;144:137–146. doi: 10.1007/s11060-019-03212-0.
PubMed
DOI
Herbst R.S. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol. Phys. 2004;59((Suppl. S2)):21–26. doi: 10.1016/j.ijrobp.2003.11.041.
PubMed
DOI
Kenney N.J., Bowman A., Korach K.S., Barrett J.C., Salomon D.S. Effect of exogenous epidermal-like growth factors on mammary gland development and differentiation in the estrogen receptor-alpha knockout (ERKO) mouse. Breast Cancer Res. Treat. 2003;79:161–173. doi: 10.1023/A:1023938510508.
PubMed
DOI
Zhang H., Berezov A., Wang Q., Zhang G., Drebin J., Murali R., Greene M.I. ErbB receptors: From oncogenes to targeted cancer therapies. J. Clin. Investig. 2007;117:2051–2058. doi: 10.1172/JCI32278.
PubMed
DOI
PMC
Kuan C.T., Wikstrand C.J., Bigner D.D. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr. Relat. Cancer. 2001;8:83–96. doi: 10.1677/erc.0.0080083.
PubMed
DOI
An Z., Aksoy O., Zheng T., Fan Q.W., Weiss W.A. Epidermal growth factor receptor and EGFRvIII in glioblastoma: Signaling pathways and targeted therapies. Oncogene. 2018;37:1561–1575. doi: 10.1038/s41388-017-0045-7.
PubMed
DOI
PMC
Matini A.H., Mofidi Naeini M., Haddad Kashani H., Vakili Z. Evaluation of Nestin and EGFR in Patients with Glioblastoma Multiforme in a Public Hospital in Iran. Asian Pac. J. Cancer Prev. 2020;21:2889–2894. doi: 10.31557/APJCP.2020.21.10.2889.
PubMed
DOI
PMC
Navarro L., San-Miguel T., Megías J., Santonja N., Calabuig S., Muñoz-Hidalgo L., Roldán P., Cerdá-Nicolás M., López-Ginés C. Identification of New Genetic Clusters in Glioblastoma Multiforme: EGFR Status and ADD3 Losses Influence Prognosis. Cells. 2020;9:2429. doi: 10.3390/cells9112429.
PubMed
DOI
PMC
Armocida D., Pesce A., Frati A., Santoro A., Salvati M. EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma? J. Neurooncol. 2020;146:275–284. doi: 10.1007/s11060-019-03364-z.
PubMed
DOI
Muñoz-Hidalgo L., San-Miguel T., Megías J., Monleón D., Navarro L., Roldán P., Cerdá-Nicolás M., López-Ginés C. Somatic copy number alterations are associated with EGFR amplification and shortened survival in patients with primary glioblastoma. Neoplasia. 2020;22:10–21. doi: 10.1016/j.neo.2019.09.001.
PubMed
DOI
PMC
Schaff L.R., Yan D., Thyparambil S., Tian Y., Cecchi F., Rosenblum M., Reiner A.S., Panageas K.S., Hembrough T., Lin A.L. Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival. J. Neurooncol. 2020;146:163–170. doi: 10.1007/s11060-019-03358-x.
PubMed
DOI
PMC
Weller M., Butowski N., Tran D.D., Recht L.D., Lim M., Hirte H., Ashby L., Mechtler L., Goldlust S.A., Iwamoto F., et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017;18:1373–1385. doi: 10.1016/S1470-2045(17)30517-X.
PubMed
DOI
Guo C., Pirozzi C.J., Lopez G.Y., Yan H. Isocitrate dehydrogenase mutations in gliomas: Mechanisms, biomarkers and therapeutic target. Curr. Opin. Neurol. 2011;24:648–652. doi: 10.1097/WCO.0b013e32834cd415.
PubMed
DOI
PMC
Xu X., Zhao J., Xu Z., Peng B., Huang Q., Arnold E., Ding J. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J. Biol. Chem. 2004;279:33946–33957. doi: 10.1074/jbc.M404298200.
PubMed
DOI
Dimitrov L., Hong C.S., Yang C., Zhuang Z., Heiss J.D. New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma. Int. J. Med. Sci. 2015;12:201–213. doi: 10.7150/ijms.11047.
PubMed
DOI
PMC
Kirollos R.W., Helmy A., Thomson S., Hutchinson P.J.A. Oxford Textbook of Neurological Surgery. Oxford University Press; Oxford, UK: 2020. 1148p.
Bascur J.P., Alegria-Arcos M., Araya-Duran I., Juritz E., Gonzalez-Nilo F.D., Almonacid D. IDH1 and IDH2 Mutants Identified in Cancer Lose Inhibition by Isocitrate Because of a Change in Their Binding Sites. 2018. [(accessed on 2 May 2019)]. Available online: https://www.biorxiv.org/content/10.1101/425025v2.full.pdf+html.
DOI
Liu X., Ling Z.Q. Role of isocitrate dehydrogenase 1/2 (IDH 1/2) gene mutations in human tumors. Histol. Histopathol. 2015;30:1155–1160. doi: 10.14670/HH-11-643.
PubMed
DOI
Molenaar R.J., Radivoyevitch T., Maciejewski J.P., van Noorden C.J., Bleeker F.E. The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. Biochim. Biophys. Acta. 2014;1846:326–341. doi: 10.1016/j.bbcan.2014.05.004.
PubMed
DOI
Kaiser R. Chirurgie Hlavových a Periferních Nervů s Atlasem Přístupů. Grada; Praha, Czech Republic: 2016. 232p.
Polívka J., Jr., Pešta M., Pitule P., Hes O., Holubec L., Kubíková T., Tonar Z. IDH1 mutation is associated with lower expression of VEGF but not microvessel formation in glioblastoma multiforme. Oncotarget. 2018;9:16462–16476. doi: 10.18632/oncotarget.24536.
PubMed
DOI
PMC
Chen N., Yu T., Gong J., Nie L., Chen X., Zhang M., Xu M., Tan J., Su Z., Zhong J., et al. IDH1/2 gene hotspot mutations in central nervous system tumours: Analysis of 922 Chinese patients. Pathology. 2016;48:675–683. doi: 10.1016/j.pathol.2016.07.010.
PubMed
DOI
Lasocki A., Gaillard F., Tacey M., Drummond K., Stuckey S. Morphologic patterns of noncontrast-enhancing tumor in glioblastoma correlate with IDH1 mutation status and patient survival. J. Clin. Neurosci. 2018;47:168–173. doi: 10.1016/j.jocn.2017.09.007.
PubMed
DOI
Goryaynov S.A., Gol’dberg M.F., Golanov A.V., Zolotova S.V., Shishkina L.V., Ryzhova M.V., Pitskhelauri D.I., Zhukov V.Y., Usachev D.Y., Belyaev A.Y., et al. Fenomen dlitel’noĭ vyzhivaemosti patsientov s glioblastomami. Chast’ I: Rol’ kliniko-demograficheskikh faktorov i mutatsii IDH1 (R 132 H) [The phenomenon of long-term survival in glioblastoma patients. Part I: The role of clinical and demographic factors and an IDH1 mutation (R 132 H)] Zh Vopr. Neirokhir Im. N. N. Burdenko. 2017;81:5–16. doi: 10.17116/neiro20178135-16.
PubMed
DOI
Paldor I., Drummond K.J., Kaye A.H. IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumor location: A case-control study. J. Clin. Neurosci. 2016;34:117–120. doi: 10.1016/j.jocn.2016.05.016.
PubMed
DOI
July J., Patricia D., Gunawan P.Y., Setiajaya H., Ginting T.E., Putra T.P., Wuisan Z., Budhiarko D., Masykura N., Prayogi G., et al. Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment. Pan Afr. Med. J. 2020;36:309. doi: 10.11604/pamj.2020.36.309.24831.
PubMed
DOI
PMC
Šlampa P. Gliomy Současná Diagnostika a Léčba; 2013; 191p. ISBN: 978-80-7345-321-3. [(accessed on 3 March 2024)]. Available online: https://webview.isho.jp/openurl?rft.genre=article&rft.issn=0301-2603&rft.volume=40&rft.issue=2&rft.spage=129.
Millward C.P., Brodbelt A.R., Haylock B., Zakaria R., Baborie A., Crooks D., Husband D., Shenoy A., Wong H., Jenkinson M.D. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy. Acta Neurochir. 2016;158:1943–1953. doi: 10.1007/s00701-016-2928-8.
PubMed
DOI
Myung J.K., Cho H.J., Kim H., Park C.-K., Lee S.H., Choi S.H., Park P., Yoon J.M., Park S.-H. Prognosis of Glioblastoma with Oligodendroglioma Component is Associated with the IDH1 Mutation and MGMT Methylation Status. Transl. Oncol. 2014;7:712–719. doi: 10.1016/j.tranon.2014.10.002.
PubMed
DOI
PMC
Boots-Sprenger S.H., Sijben A., Rijntjes J., Tops B.B.J., Idema A.J., Rivera A.L., E Bleeker F., Gijtenbeek A.M., Diefes K., Heathcock L., et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: Use with caution. Mod. Pathol. 2013;26:922–929. doi: 10.1038/modpathol.2012.166.
PubMed
DOI
Kamoshima Y., Motegi H., Terasaka S., Kobayashi H., Yamaguchi S., Murata J., Tanaka S., Houkin K. Analyses of IDH1 mutation and MGMT promoter methylation status for 5 cases of long-term survivors with glioblastoma. No Shinkei Geka. 2012;40:129–135.
PubMed
Wang K., Wang Y.-Y., Ma J., Wang J.-F., Li S.-W., Jiang T., Dai J.-P. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation. Asian Pac. J. Cancer Prev. 2014;15:10893–10898. doi: 10.7314/APJCP.2014.15.24.10893.
PubMed
DOI
Yang P., Zhang W., Wang Y., Peng X., Chen B., Qiu X., Li G., Li S., Wu C., Yao K., et al. IDH mutation and MGMT promoter methylation in glioblastoma: Results of a prospective registry. Oncotarget. 2015;6:40896–40906. doi: 10.18632/oncotarget.5683.
PubMed
DOI
PMC
Nguyen H.N., Lie A., Li T., Chowdhury R., Liu F., Ozer B., Wei B., Green R.M., Ellingson B.M., Wang H.-J., et al. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy. Neuro Oncol. 2017;19:394–404. doi: 10.1093/neuonc/now189.
PubMed
DOI
PMC
Ayoub Z., Geara F., Najjar M., Comair Y., Khoueiry-Zgheib N., Khoueiry P., Mahfouz R., Boulos F.I., Kamar F.G., Andraos T., et al. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region. Clin. Neurol. Neurosurg. 2019;182:92–97. doi: 10.1016/j.clineuro.2019.04.008.
PubMed
DOI
Malmström A., Grønberg B.H., Marosi C., Stupp R., Frappaz D., Schultz H., Abacioglu U., Tavelin B., Lhermitte B., E Hegi M., et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13:916–926. doi: 10.1016/S1470-2045(12)70265-6.
PubMed
DOI
van den Bent M.J., Dubbink H.J., Sanson M., Van Der Lee-Haarloo C.R., Hegi M., Jeuken J.W., Ibdaih A., Brandes A.A., Taphoorn M.J., Frenay M., et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: A report from EORTC Brain Tumor Group Study 26951. J. Clin. Oncol. 2009;27:5881–5886. doi: 10.1200/JCO.2009.24.1034.
PubMed
DOI
PMC
Li H., Li J., Cheng G., Zhang J., Li X. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy. Clin. Neurol. Neurosurg. 2016;151:31–36. doi: 10.1016/j.clineuro.2016.10.004.
PubMed
DOI
Arita H., Yamasaki K., Matsushita Y., Nakamura T., Shimokawa A., Takami H., Tanaka S., Mukasa A., Shirahata M., Shimizu S., et al. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol. Commun. 2016;4:79. doi: 10.1186/s40478-016-0351-2.
PubMed
DOI
PMC
Vuong H.G., Nguyen T.Q., Ngo T.N.M., Nguyen H.C., Fung K.M., Dunn I.F. The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: A meta-analysis. BMC Cancer. 2020;20:897. doi: 10.1186/s12885-020-07364-5.
PubMed
DOI
PMC
Shu C., Wang Q., Yan X., Wang J. The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival. Cancer Med. 2018;7:3704–3712. doi: 10.1002/cam4.1666.
PubMed
DOI
PMC
Ligresti G., Militello L., Steelman L.S., Cavallaro A., Basile F., Nicoletti F., Stivala F., McCubrey J.A., Libra M. PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches. Cell Cycle. 2009;8:1352–1358. doi: 10.4161/cc.8.9.8255.
PubMed
DOI
PMC
Gallia G.L., Rand V., Siu I.-M., Eberhart C.G., James C.D., Marie S.K., Oba-Shinjo S.M., Carlotti C.G., Caballero O.L., Simpson A.J., et al. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol. Cancer Res. 2006;4:709–714. doi: 10.1158/1541-7786.MCR-06-0172.
PubMed
DOI
McNeill R.S., Stroobant E.E., Smithberger E., Canoutas D.A., Butler M.K., Shelton A.K., Patel S.D., Limas J.C., Skinner K.R., Bash R.E., et al. PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition. PLoS ONE. 2018;13:e0200014. doi: 10.1371/journal.pone.0200014.
PubMed
DOI
PMC
Tanaka S., Batchelor T.T., Iafrate A.J., Dias-Santagata D., Borger D.R., Ellisen L.W., Yang D., Louis D.N., Cahill D.P., Chi A.S. PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma. Acta Neuropathol. Commun. 2019;7:66. doi: 10.1186/s40478-019-0720-8.
PubMed
DOI
PMC
Quayle S.N., Lee J.Y., Cheung L.W.T., Ding L., Wiedemeyer R., Dewan R.W., Huang-Hobbs E., Zhuang L., Wilson R.K., Ligon K.L., et al. Somatic mutations of PIK3R1 promote gliomagenesis. PLoS ONE. 2012;7:e49466. doi: 10.1371/journal.pone.0049466.
PubMed
DOI
PMC
Weber G.L., Parat M.O., Binder Z.A., Gallia G.L., Riggins G.J. Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget. 2011;2:833–849. doi: 10.18632/oncotarget.346.
PubMed
DOI
PMC
Chu E.C., Tarnawski A.S. PTEN regulatory functions in tumor suppression and cell biology. Med. Sci. Monit. 2004;10:RA235–RA241.
PubMed
Koshiyama D.B., Trevisan P., Graziadio C., Rosa R.F.M., Cunegatto B., Scholl J., Provenzi V.O., de Sá A.P., Soares F.P., Velho M.C., et al. Frequency and clinical significance of chromosome 7 and 10 aneuploidies, amplification of the EGFR gene, deletion of PTEN and TP53 genes, and 1p/19q deficiency in a sample of adult patients diagnosed with glioblastoma from Southern Brazil. J. Neurooncol. 2017;135:465–472. doi: 10.1007/s11060-017-2606-6.
PubMed
DOI
Xu J., Li Z., Wang J., Chen H., Fang J.Y. Combined PTEN Mutation and Protein Expression Associate with Overall and Disease-Free Survival of Glioblastoma Patients. Transl. Oncol. 2014;7:196–205.e1. doi: 10.1016/j.tranon.2014.02.004.
PubMed
DOI
PMC
Carico C., Nuño M., Mukherjee D., Elramsisy A., Dantis J., Hu J., Rudnick J., Yu J.S., Black K.L., Bannykh S.I., et al. Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era. PLoS ONE. 2012;7:e33684. doi: 10.1371/journal.pone.0033684.
PubMed
DOI
PMC
Kraus J.A., Glesmann N., Beck M., Krex D., Klockgether T., Schackert G., Schlegel U. Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J. Neurooncol. 2000;48:89–94. doi: 10.1023/A:1006402614838.
PubMed
DOI
Tadipatri R., Lyon K., Azadi A., Fonkem E. A view of the epidemiologic landscape: How population-based studies can lend novel insights regarding the pathophysiology of glioblastoma. Chin. Clin. Oncol. 2021;10:35. doi: 10.21037/cco.2020.02.07.
PubMed
DOI
Ermoian R.P., Furniss C.S., Lamborn K.R., Basila D., Berger M.S., Gottschalk A.R., Nicholas M.K., Stokoe D., A Haas-Kogan D. Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin. Cancer Res. 2002;8:1100–1106.
PubMed
Ruano Y., Ribalta T., de Lope R., Campos-Martín Y., Fiaño C., Pérez-Magán E., Hernández-Moneo J.-L., Mollejo M., Meléndez B. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration. Am. J. Clin. Pathol. 2009;131:257–263. doi: 10.1309/AJCP64YBDVCTIRWV.
PubMed
DOI
Bäcklund L.M., Nilsson B.R., Goike H.M., E Schmidt E., Liu L., Ichimura K., Collins V.P. Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN. Clin. Cancer Res. 2003;9:4151–4158.
PubMed
Shampay J., Blackburn E.H. Generation of telomere-length heterogeneity in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA. 1988;85:534–538. doi: 10.1073/pnas.85.2.534.
PubMed
DOI
PMC
Nonoguchi N., Ohta T., Oh J.E., Kim Y.H., Kleihues P., Ohgaki H. TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol. 2013;126:931–937. doi: 10.1007/s00401-013-1163-0.
PubMed
DOI
Spiegl-Kreinecker S., Lötsch D., Ghanim B., Pirker C., Mohr T., Laaber M., Weis S., Olschowski A., Webersinke G., Pichler J., et al. Prognostic quality of activating TERT promoter mutations in glioblastoma: Interaction with the rs2853669 polymorphism and patient age at diagnosis. Neuro Oncol. 2015;17:1231–1240. doi: 10.1093/neuonc/nov010.
PubMed
DOI
PMC
Mosrati M.A., Malmström A., Lysiak M., Krysztofiak A., Hallbeck M., Milos P., Hallbeck A.-L., Bratthäll C., Strandéus M., Stenmark-Askmalm M., et al. TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma. Oncotarget. 2015;6:16663–16673. doi: 10.18632/oncotarget.4389.
PubMed
DOI
PMC
Simon M., Hosen I., Gousias K., Rachakonda S., Heidenreich B., Gessi M., Schramm J., Hemminki K., Waha A., Kumar R. TERT promoter mutations: A novel independent prognostic factor in primary glioblastomas. Neuro Oncol. 2015;17:45–52. doi: 10.1093/neuonc/nou158.
PubMed
DOI
PMC
Kikuchi Z., Shibahara I., Yamaki T., Yoshioka E., Shofuda T., Ohe R., Matsuda K.-I., Saito R., Kanamori M., Kanemura Y., et al. TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastoma. Neurooncol. Adv. 2020;2:vdaa114. doi: 10.1093/noajnl/vdaa114.
PubMed
DOI
PMC
Fan H.-C., Chen C.-M., Chi C.-S., Tsai J.-D., Chiang K.-L., Chang Y.-K., Lin S.-Z., Harn H.-J. Targeting Telomerase and ATRX/DAXX Inducing Tumor Senescence and Apoptosis in the Malignant Glioma. Int. J. Mol. Sci. 2019;20:200. doi: 10.3390/ijms20010200.
PubMed
DOI
PMC
Novotná B., Mareš J. Vývojová Biologie Pro Mediky. 1. vydání. Karolinum; Praha, Czech Republic: 2005. 99p.
Zhang Y., Dube C., Gibert M., Jr., Cruickshanks N., Wang B., Coughlan M., Yang Y., Setiady I., Deveau C., Saoud K., et al. The p53 Pathway in Glioblastoma. Cancers. 2018;10:297. doi: 10.3390/cancers10090297.
PubMed
DOI
PMC
Aubrey B.J., Strasser A., Kelly G.L. Tumor-Suppressor Functions of the TP53 Pathway. Cold Spring Harb. Perspect. Med. 2016;6:a026062. doi: 10.1101/cshperspect.a026062.
PubMed
DOI
PMC
Lee Y.-J., Seo H.W., Baek J.-H., Lim S.H., Hwang S.-G., Kim E.H. Gene expression profiling of glioblastoma cell lines depending on TP53 status after tumor-treating fields (TTFields) treatment. Sci. Rep. 2020;10:12272. doi: 10.1038/s41598-020-68473-6.
PubMed
DOI
PMC
Wang X., Chen J.X., Liu J.P., You C., Liu Y.H., Mao Q. Gain of function of mutant TP53 in glioblastoma: Prognosis and response to temozolomide. Ann. Surg. Oncol. 2014;21:1337–1344. doi: 10.1245/s10434-013-3380-0.
PubMed
DOI
Homma T., Fukushima T., Vaccarella S., Yonekawa Y., Di Patre P.L., Franceschi S., Ohgaki H. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J. Neuropathol. Exp. Neurol. 2006;65:846–854. doi: 10.1097/01.jnen.0000235118.75182.94.
PubMed
DOI
Cantero D., Mollejo M., Sepúlveda J.M., D’haene N., Gutiérrez-Guamán M.J., de Lope R., Fiaño C., Castresana J.S., Lebrun L., A Rey J., et al. TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors. Neurooncol. Adv. 2020;2:vdz059. doi: 10.1093/noajnl/vdz059.
PubMed
DOI
PMC
Weller M., Felsberg J., Hartmann C., Berger H., Steinbach J.P., Schramm J., Westphal M., Schackert G., Simon M., Tonn J.C., et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: A prospective translational study of the German Glioma Network. J. Clin. Oncol. 2009;27:5743–5750. doi: 10.1200/JCO.2009.23.0805.
PubMed
DOI
Li S., Wang C., Chen J., Lan Y., Zhang W., Kang Z., Zheng Y., Zhang R., Yu J., Li W. Signaling pathways in brain tumors and therapeutic interventions. Signal Transduct. Target. Ther. 2023;8:8. doi: 10.1038/s41392-022-01260-z.
PubMed
DOI
PMC